CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Inotuzumab Ozogamicin 治疗 CD19-CAR-T 细胞治疗后复发/难治性 B 细胞急性淋巴细胞白血病儿童及年轻成人患者的疗效与毒性
英文原题：Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19-Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19-Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们回顾性分析了9例儿童和年轻成人患者的结局，这些患者在接受CD19-CAR-T 细胞治疗（CAR-T）后，因复发/难治性（R/R）B-急性淋巴细胞白血病（ALL）接受了inotuzumab ozogamicin（InO）治疗。InO第1周期后，总缓解率为77.8%；66.7%达到可测量残留病（MRD）阴性缓解。1年无事件生存率（EFS）为37.5%；1年总生存率（OS）为50%；2年EFS为37.5%；2年OS为37.5%。存活者中位随访时间为2.9年（0.5-4.7）。显著不良事件包括持续性血细胞减少、肝毒性以及移植后肝窦阻塞综合征。InO作为CD19-CART后R/R B-ALL儿童和年轻成人的治疗显示出有希望的疗效。InO治疗前有髓外疾病以及InO第1周期后MRD阳性与不良结局相关。
展开英文摘要原文
We retrospectively analyzed outcomes for nine children and young adults who were treated with inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) B-acute lymphoblastic leukemia (ALL) after CD19-chimeric antigen receptor T-cell therapy (CART). After InO cycle 1, overall response rate was 77. 8%; 66. 7% achieved measurable residual disease (MRD)-negative remission. One-year event-free survival (EFS) was 37. 5%; 1-year overall survival (OS) was 50%; 2-year EFS was 37.
5%; 2-year OS was 37. 5%. Median survivor follow-up is 2. 9 years (0. 5-4. 7). Significant adverse events included prolonged cytopenias, hepatotoxicity, and post-transplant sinusoidal obstructive sydrome. InO showed promising efficacy as treatment for children and young adults with R/R B-ALL after CD19-CART. Extramedullary disease prior to InO and positive MRD after InO cycle 1 were associated with poor outcomes.
论文信息
- 作者
- Ogrodnik P、Anderson E、Gloude N、Schiff D
- 单位
- Division of Pediatric Hematology/Oncology, Rady Children's Hospital San Diego, San Diego, California, USA.United States
- 期刊
- Pediatric blood & cancer2025 Nov
- 原文标识
- PubMed 40879090 · DOI 10.1002/pbc.32013